INTRODUCTION {#sec1-1}
============

Anemia is one of the most important complications of end-stage renal disease (ESRD), especially in patients on regular hemodialysis.\[[@ref1]\] In these patients, anemia can lead to other morbidities such as a decrease in the quality of life and increased cardiovascular complications and also increased mortality rate. This is why an understanding of the mechanisms and factors involved in anemia and its treatment on ESRD patients is crucial.\[[@ref2][@ref3][@ref4][@ref5]\]

The main cause of anemia in these patients is lowered erythropoietin (EPO) secretion from kidneys but there are also other suggested factors involved in the development and severity of it such as Vitamin D deficiency. The primary treatment of anemia in ESRD patients are EPO stimulating agents (ESA) including injectable EPO.\[[@ref1]\] Although a gradual hyporesponsiveness might develop in 10% of these patients so that they may need an increased dosage of EPO to maintain their hemoglobin (Hb) concentration in the aimed range.\[[@ref6][@ref7][@ref8][@ref9]\]

Even though there are several different mechanisms suggested for EPO hyporesponsiveness such as Iron deficiency, B12 deficiency, secondary hyperparathyroidism, chronic inflammation, and malignancies; but none of these can thoroughly explain this phenomenon in ESRD patients.\[[@ref10][@ref11][@ref12][@ref13]\] On the other hand, it has been proved that an increased hyporesponsiveness to EPO is associated with increased rate of mortality.\[[@ref14][@ref15][@ref16][@ref17]\]

In recent years, a growing number of studies have suggested that Vitamin D deficiency could be one of the risk factors involved in this hyporesponsiveness.\[[@ref18][@ref19][@ref20]\] The prevalence of Vitamin D deficiency (serum concentration smaller than 30 ng/dl) in ESRD patients is a lot higher than in the other populations, so that 75% of these patients are estimated to suffer from Vitamin D deficiency. This could be due to lowered renal hydroxylase enzyme, decreased sun exposure, and malnutrition.\[[@ref20][@ref21][@ref22]\] It is also known that Vitamin D along with EPO has a synergic effect, the stimulation of bone marrow precursor cells, and red blood cell formation. Furthermore, several tissues express the Vitamin D receptor and are hence able to transform it into the active form, so the level of Vitamin D could be effective on the function of these tissues.\[[@ref21][@ref23][@ref24]\]

Although previous studies have worked on the correlation between Vitamin D administration in ESRD patients and required doses of EPO; there is no available double-blind, placebo-controlled clinical trial on the effect of Vitamin D deficiency on the required dose of EPO in ESRD patients on hemodialysis yet.

MATERIALS AND METHODS {#sec1-2}
=====================

Participants {#sec2-1}
------------

This study is a double-blind, randomized, control clinical trial (placebo control) on ESRD patients on hemodialysis in Amin and Noor and Hospitals (Isfahan, Iran) between the years 2013 and 2014. The patients were all between 18 and 80 years of age suffering from anemia and Vitamin D deficiency and were referred to the above hospitals. The project was also registered at IRCT: IRCT201505152417N17.

Study design {#sec2-2}
------------

The ESRD patients needing hemodialysis in Amin and Noor hospitals were entered in the study. All of them were tested for Hb concentration and those with a measured amount lower than 11 g/dl were accepted for the study as anemic cases. Considering other causes of anemia, serum ferritin, iron, and total iron-binding capacity were checked. All of these anemic patients were tested for Vitamin D level and the levels smaller than 30 ng/dl were considered as Vitamin D deficient patients. The patients with anemia (Hb con. \<11 g/dl) and Vitamin D deficiency\[[@ref25]\] were assigned to two groups using random sampling method. The angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers prescribed patients were compared in two groups and sex- and age-matching was done. The minimum volume of each group was calculated to be 32 patients. The intervention group were administered a 50,000 IU Vitamin D pear weekly for 12 weeks and then every three weeks until each patient had taken 650,000 IU Vitamin D in the course of the study. The treatment was performed in a 4-month period and the control group was given placebo pearls in exactly the same pattern. The Vitamin D and placebo pearls were both prepared by Zahravi Pharmaceutical Co. (Tabriz, Iran). The Vitamin D level was measured for both groups at the beginning of the study and after 4 months, though the study and the Hb concentration was tested monthly. The weekly and cumulative EPO dosage was also recorded for each patient. The treatment approach for anemia was decided using Kidney Disease Improving Global Outcomes guidelines for both groups.\[[@ref23]\]

Criteria for entering the study {#sec2-3}
-------------------------------

Patients must have been between 18 and 80 years of age.Patients must have suffered from ESRD and on hemodialysis for 3 months at least.Patients must have had an Hb con. lower than 11 g/dl.Patients must have had Vitamin D deficiency (25\[OH\] Vitamin D \<30 ng/ml).

Criteria to be omitted from the study {#sec2-4}
-------------------------------------

Patients with serum Calcium of over 9.5.Patients with serum Phosphate of over 5.5.Noncompliant patients.Patients who were treated by medications that could affect their Hb level such as immunosuppressants.

Statistical methods {#sec2-5}
-------------------

The results analyzed and showed in tables and graphs using SPSS version 22 (SPSS Inc, Chicago, IL) and descriptive results were obtained. A multivariate analysis of variance (ANOVA) was done for Hb levels, serum Vitamin D values, and EPO dosages before and after the study in two groups. Pearson statistical test was used to determine the correlation between age, sex, body mass index (BMI), and EPO dosages. Moreover, also two-way ANOVA was done to compare EPO dosages according to patient\'s sex in two groups before and after the intervention. *P* \< 0.05 was considered as statistically significant.

Ethical considerations {#sec2-6}
----------------------

This study was approved by Research Ethics Committee of the Research Department (research project number 292280). Considering that this study is a clinical trial, a specific questionnaire was filled and approved by the Research Department. Patients were completely informed about the process of the study, possible side effects, and other considerations, and were then volunteered to participate the study.

RESULTS {#sec1-3}
=======

The patients characteristics and demographic data {#sec2-7}
-------------------------------------------------

In this double-blind clinical trial, 64 ESRD patients on hemodialysis in Isfahan\'s Amin and Noor Hospitals in 2013 and 2014 were studied into two groups of intervention and control \[[Figure 1](#F1){ref-type="fig"}\]. The sex ratio and age range was the same in both groups. The age was between 20 and 78 years old and 24 patients (37.5%) were between 51 and 60 years \[[Table 1](#T1){ref-type="table"}\].

![Clinical trial diagram of patients](JRMS-20-745-g001){#F1}

###### 

Basic characteristics of the study population

![](JRMS-20-745-g002)

Effects of Vitamin D administration on hemoglobin levels, erythropoietin dosage, and serum (OH) Vitamin D levels {#sec2-8}
----------------------------------------------------------------------------------------------------------------

The Hb and Vitamin D levels were measured in both groups before and after the treatment and the data are shown based on gender in [Table 2](#T2){ref-type="table"}. Before the study, seven patients in the control group and five patients in the intervention group had serum (OH) Vitamin D levels under 10 ng/dl and the others had 20-30 ng/dl serum Vitamin D levels but after the study, none of them were under 10 ng/dl. Average of Hb levels of patients in the control group before and after the study was 9.19 and 10.14, respectively, and in the intervention group it was 9.93 and 11.09, respectively. Vitamin D toxicity was not seen in any of the participants during and after the study.

###### 

Serum 25(OH) Vitamin D levels of the patients before and after the study in both groups

![](JRMS-20-745-g003)

Using three variant ANOVA and co-variance, the effects of sex, BMI, and age on Hb and Vitamin D levels, and the required dose of EPO were controlled in both groups and no significant correlation was detected between these three variants and the Hb and Vitamin D levels (power of statistical test: 80%).

Although a significant correlation was found between BMI and the required dose of EPO in both groups (*P* = 0.004, R = 0.5), the higher the BMI, more the required dose of EPO \[[Table 3](#T3){ref-type="table"}\].

###### 

The association between the required doses of erythropoitin and patients BMI

![](JRMS-20-745-g004)

A comparison among the average Hb concentration change, the intervention, and control groups showed no significant difference; with 80% power of statistical test \[[Table 4](#T4){ref-type="table"}\].

###### 

Hb levels of the patients before and after the study in both groups

![](JRMS-20-745-g005)

The change in Vitamin D level also demonstrated a statistically significant difference between the two groups (*P* \< 0.001). Average of Vitamin D levels had a 58.04 ng/ml increase in the intervention group; the amount of which was only 1.25 in the control group \[[Figure 2](#F2){ref-type="fig"}\].

![Vitamin D levels before and after the study in both groups](JRMS-20-745-g006){#F2}

A comparison between the required doses of EPO in the two groups showed a decrease in the treatment group (*P* \< 0.001) while its changes was not statistically significant in the control group \[[Figure 3](#F3){ref-type="fig"}\].

![Dosages of erythropoietin in both groups before and after the study](JRMS-20-745-g007){#F3}

DISCUSSION {#sec1-4}
==========

The goal of this study was to approve the effect of Vitamin D administration on the dose of EPO need in ESRD patients to achieve the target Hb concentration while on hemodialysis, the serum level of Vitamin D was elevated to an average of 79 ng/ml in all of the patients in the treatment group after taking 650,000 IU of Vitamin D. The correlation between BMI and EPO dosages is because of this fact that in patients with more weight, the need for almost all drugs is more than the patients with lower weight. After the administration of Vitamin D, the treatment group showed a significant decrease in the required dose of EPO while this same parameter had a slight but not statistically significant increase in the control group. Since several different factors are considered to be involved in hyporesponsiveness of ESRD patients to ESA treatments, such as inflammation, secondary hyperparathyroidism, etc., here the effect of Vitamin D administration in the treatment and control group was predictable.

In a study by Kumar *et al*.\[[@ref25]\] a group of ESRD patients were administered by 200,000-350,000 IU of Vitamin D and during the course of the study, 44% of the patients had reached a Vitamin D level of over 30 ng\\ml, while in the study by Saab *et al*.\[[@ref26]\] the administration of 350,000 IU throughout 6 months could help at least 95% of the patients to achieve the target level of over 30 ng/ml. The difference between these two results is suggested to be due to the different seasons of study and the effect of sunlight on Vitamin D level. Nevertheless, we decided to give Vitamin D to the patients as suggested by Kumar *et al*.; and this seemed to be a sufficient amount for all the patients to surpass the target level of Vitamin D. In addition, the Vitamin D elevation response to this administration was the same in male and female patients. The Hb level in both groups was maintained at 10-11 in both groups throughout the study.

Kumar *et al*. found that the required dose of EPO in hemodialysed ESRD patients decreases with the administration of Vitamin D. Furthermore, Kiss *et al*. discovered correlations between Vitamin D level and Hb concentration and the required dose of EPO in ESRD patients, while Porter *et al*. found no such relationship which is in contrast to the findings of the current study.\[[@ref1][@ref27]\]

The mechanism involved in the effect of Vitamin D on the required EPO dosage in ESRD patients is unknown but a number of possible mechanisms could be suggested. First, both *in vitro* and *in vivo* studies have shown the effect of Vitamin D on bone marrow precursor cells and their efficacy in the formation of red blood cells. In conjunction with that, this vitamin is known to decrease inflammation in the tissues which might decrease the hyporesponsiveness to ESAs to some extent. And at last, the fact that many types of tissues express the Vitamin D receptors such as parathyroid and erythroid precursor cells, both of which are known as the tissues involved in ESA hyporesponsiveness, suggests that the modulation of these tissues with Vitamin D might increase the response to EPO treatment.\[[@ref1][@ref26][@ref27]\]

The strong point of this study is its methodology which makes it the first, double-blind, case-control clinical trial on this matter.

Several downsides could also be mentioned such as the study having been done in a hemodialysis center which means that there were no patients on peritoneal dialysis in the study. In addition, the number of cases was small and we suggest that studies with larger sample populations of ESRD patients might be helpful to further clear the matter.

CONCLUSION {#sec1-5}
==========

We state that the administration of Vitamin D in ESRD patients could help reduce the required dose of EPO during the courses of hemodialysis. Also, the administration of this vitamin-based supplements on the current guideline helps almost all patients to achieve its sufficient level. Basically, the treatment with Vitamin D in ESRD patients could be helpful due to its very small side effects and its probable efficacy in reducing other complications such as anemia.
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